In accordance with Biovitrum stock option program 2006:5 TO6
2006/2008, 400,778 new shares have been issued at the price SEK 59.00
per share, resulting in Biovitrum being provided funds of a total of
SEK 23,645,902.00. The is no remaining stock options in the stock
option program 2006:5 TO6 2006/2008.
After the share issue the outstanding number of shares in Biovitrum
is 50,680,316.
For more information please contact:
Biovitrum
Göran Arvidson, CFO
Phone: +46 8 697 23 68
Erik Kinnman, VP Investor Relations
Phone: +46 8 697 21 50
erik.kinnman@biovitrum.com
About Biovitrum
Biovitrum is an international pharmaceutical company that markets
specialist pharmaceuticals in several regions globally. Using its
expertise and experience Biovitrum takes scientific innovation to
patients with significant unmet medical need. Research expertise and
capabilities are focused on development and production of
biotechnology therapeutics within our prioritized areas of
hemophilia, inflammation/autoimmune diseases, cancer supportive care
and malabsorption. The company has revenues of approximately SEK 1.2
billion and around 400 employees. The company head office is located
in Sweden and it is listed on the Stockholm OMX Nordic Exchange. For
more information please visit www.biovitrum.com.
Biovitrum AB (publ) may be required to disclose the information
provided herein pursuant to the Swedish Securities Markets Act. The
information was provided for public release on June 30, 2009 at 17:00
p.m. CET.
